Teva Pharmaceuticals USA Recalls
An assortment of pharmaceutical pills (representative file photo). Specific recalled product: see recall details below. Photo: Michael Nutt / Wikimedia Commons (CC BY-SA 2.0).
- Recalls in database
- 18
- Agency
- FDA
- Years covered
- 2025–2026
Teva Pharmaceuticals USA has 9 recall events across 18 FDA product-line records. Teva makes generic and specialty medications; the records here are FDA drug recalls, each tied to affected lots. The events span 2025–2026.
Use this hub to look up a recalled Teva medication by lot. Each row links to the FDA enforcement record with the recall classification and the firm's corrective action; each row's hazard label reflects that record's own classification.
How this hub is built. This page collects 9 recall events tied to Teva Pharmaceuticals USA (across 18 product-line records) in the current 411 Press recall dataset. A note on counting. The three agencies package recalls differently. NHTSA issues one record per safety campaign; the CPSC issues one per recall; the FDA issues one per affected product line, so a single FDA recall can appear as dozens of records. Counting raw records would push FDA-heavy brands artificially to the top. The counts here are recall EVENTS — distinct agency events — with the FDA product-line record total shown alongside wherever the two differ. Records are grouped by a normalized version of the recalling firm's name (normalizer version 2026-07-28.C3.2). Parent, subsidiary, and "doing business as" relationships are not merged unless the agency data states them, so a corporate family can appear under more than one name. Regulator for these records: FDA. They were published 2025–2026. An event count reflects how much recall activity fell inside the current dataset — not a ranking of relative safety. Larger manufacturers and higher-volume product lines generate more recall activity. This is the current dataset, not an all-time total, and it grows as new notices are ingested. Every row links to the original agency notice.
2026 (14)
- Class II
Octreotide Acetate for Injectable Suspension
Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the contract manufacturer.
- Class II
Claravis (isotretinoin capsule, USP)
Failed Impurities/Degradation Specifications: Out of specification for specific impurity Tretinoin
- Class II
Clonidine Transdermal System
CGMP Deviations: use of an unapproved raw material
- Class II
Clonidine Transdermal System
CGMP Deviations: use of an unapproved raw material
- Class II
Clonidine Transdermal System
CGMP Deviations: use of an unapproved raw material
- Class II
Octreotide Acetate for Injectable Suspension
Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the contract manufacturer.
- Class II
Octreotide Acetate for Injectable Suspension
Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the contract manufacturer.
- Class II
Octreotide Acetate for Injectable Suspension
Lack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the contract manufacturer.
- Class II
Metoprolol Succinate Extended-Release Tablets
Failed Dissolution Specifications
- Class II
Metoprolol Succinate Extended-Release Tablets
Failed Dissolution Specifications
- Class II
Metoprolol Succinate Extended-Release Tablets
Failed Dissolution Specifications
- Class II
Metoprolol Succinate Extended-Release Tablets
Failed Dissolution Specifications
- Class II
Isotretinoin Capsules
Superpotent and Subpotent
- Class II
Isotretinoin Capsules
Superpotent and Subpotent
2025 (4)
- Class III
Carton label: Testosterone Gel 1%
Defective Container - A defect in the side-seal which allows leakage of product.
- Class II
Amoxicillin and Clavulanate Potassium for Oral Suspension USP
Subpotent drug; Clavulanate Potassium component
- Class II
Prazosin Hydrochloride
CGMP Deviations-Test results for N-nitroso Prazosin impurity C that are above the Carcinogenic Potency Categorization Approach (CPCA) acceptable intake limit for the above specified lots.
- Class II
Prazosin Hydrochloride
CGMP Deviations-Test results for N-nitroso Prazosin impurity C that are above the Carcinogenic Potency Categorization Approach (CPCA) acceptable intake limit for the above specified lots.